About us

Our name Enara Bio™ is derived from an Arabic word meaning illumination, enlightenment and bringing light into the darkness.

We are the leaders in exploring the hidden depths of cancer and T-cell biology to discover and characterize Dark Antigens™, a novel class of shared immunotherapy targets that arise from altered cellular processes in cancer cells. We believe that Dark Antigens have the core attributes that will enable cancer immunotherapies to improve treatment outcomes for broad patient populations.

Enara Bio is backed by prominent life science investors, including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital and SV Health Investors. We collaborate with world-leading companies and academic institutions, such as Boehringer Ingelheim and the Francis Crick Institute, to help drive our differentiated science-led approach.

Enara Bio Our Story Poster

Leadership Team

Andrew Fadden
Chief Business Officer
Kevin Pojasek
President and Chief Executive Officer
David Watson
Chief Operating Officer
Sophie Papa
Chief Medical Officer and Head of Translational Science
Joseph Dukes
Chief Scientific Officer

Board of Directors

Scientific Advisory Board

Investors

Bauke Anninga

Director

Bauke Anninga, PhD, joined M Ventures in September 2019 and is currently an Investment Director in the Biotechnology team.

Before joining M Ventures, Bauke worked at Jefferies International for two years in the Healthcare Investment Banking group in London (UK). During his time at Jefferies, he advised on several financings and M&A transactions across the biotechnology, pharmaceutical and medical devices sectors. Before that, he was involved in a boutique life-science investment sourcing and due diligence company in Cambridge (UK). He also co-founded the Innovation Forum (UK), which is a global network and accelerator for science-based ventures.

Bauke has a PhD in Cancer Studies from King’s College London (UK) and an MSc in Technical Medicine from the University of Twente (The Netherlands). Bauke is based in Amsterdam.